The 1st China Pharmaceutical Innovation Conference (CPIC 2026)  hosted by Tonacea, will be held July 22–24, 2026 at the National Exhibition and Convention Center (NECC) in Shanghai.

CPIC will establish a model of "China Innovation – Global Partnerships – Shanghai Dealmaking". As the premier gateway for international capital to navigate China’s innovation ecosystem, and a strategic hub for Chinese pharmaceutical companies to scale globally, CPIC will undoubtedly set the benchmark for investment and partnership in the healthcare industry. CPIC will feature dozens of specialized sessions covering hot topics and future directions in healthcare innovation investment and globalization.

CNS drug development stands on the eve of a new breakthrough. The full agenda for the "CNS Novel Drug Development Session," organized by Tonacea in collaboration with Hanshu Bio and Quark Pharmaceuticals, is officially released today. The session brings together top R&D experts from around the world to decode key technologies such as novel CNS targets and mechanisms, clinical development, and gene editing, as well as to discuss cutting-edge topics including CNS disease treatments and global registration strategies for innovative drugs. It aims to build a professional exchange platform for R&D innovation, clinical translation, industry collaboration, and global partnerships in the CNS field. From July 22 to 24 at the National Exhibition and Convention Center (Shanghai), we look forward to welcoming you to this feast of ideas in CNS R&D.

Agenda

Co-hosted by: Hanshu Biotech, Quark Pharm

Development of New Molecular Entity Drugs for Antipsychotic Indications
Tian Jingwei: Executive Vice President of R&D, Luye Pharma Group; Dean, School of Pharmacy, Yantai University

Medical Use and Market Prospects of Modified Psychedelics in Light of the FDA's New Guidance and Trump's Executive Order
Shen Huajiong: Founder & CEO, NeuShen Therapeutics

“PRODEGRE ATLAS – A Protein Degradation Innovation Platform to Enable Breakthrough Therapies for CNS Disorders”
Tan Shen: Co-Founder & CEO, Pridarray Biotech

Universal iPSC-Derived Cell Therapy for Brain Injury-Related Disorders
Fan Jing: Founder & CEO, Hopstem Biotechnology

Development of a Novel Small Molecule Drug for Stroke
Chen Rong: Deputy General Manager, Ningen Pharma

Development and Global Pathway of QP001 Injection
Yu Sen: VP, Qingpu Biopharma

Preliminary Validation of iPSC-Based Therapies for CNS Diseases Derived from the SISBAR Core Technology Platform
Wu Lanlin: CEO, Yuesai Biotechnology

Expanding the Extrabepatic Application of Small Nucleic Acid Drugs – R&D Progress in CNS Diseases
Gao Shan: Senior Vice President & Chief Scientist, Ribo Life Science

Research Progress of Cyclopolysaccharide Analog AMCDx Platform in CNS Diseases
Qi Youmao: Chairman, Aomu Pharma; Head of Academician Workstation; Chief Scientist

The Path to Clinical Translation of Innovative Biopharmaceuticals – Opportunities, Challenges, and Collaboration
Si Tianmei: Vice President, Peking University Sixth Hospital; Deputy Director, Institute of Mental Health

Frontier Technology in Innovative Drug Development
Isaac Cheng: VP of Research, Suntec Medical

Discovery and Development of a Novel Dual-Target, Non-Opioid Potent Analgesic
Sheng Xijun: Director, Innovation Research Center, Yichang Humanwell

Panel Discussion – The Future of CNS Drug R&D
Hei Yongjiang: Founder, Huisibo Biotech
Fang Qun: Chief Scientific Officer, Yisi Biotech; Head, Brain Science Innovation R&D Center
Li Qun: General Manager, Saipute
Wang Bingjie: CBO, Sunshine Angene Biotech

More content to be confirmed...